Pharmacological Nrf2 activators only modestly increased Nrf2 activity and decreased intracellular ROS levels, with beneficial effects against obesity, compared with the effects of genetic modifications [51]. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.